234 related articles for article (PubMed ID: 25788426)
61. [Pathogenetic aspectics of nephrotic syndrome].
Walz G
Internist (Berl); 2003 Sep; 44(9):1075-82. PubMed ID: 14566460
[TBL] [Abstract][Full Text] [Related]
62. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
63. Pathophysiology of experimental nephrotic syndrome induced by puromicyn aminonucleoside in rats. III. Effect of captopril, an angiotensin converting enzyme inhibitor, on proteinuria and sodium retention.
Pedraza-Chaverrí J; Cruz C; Chávez MT; Ibarra-Rubio ME; Tapia E; Peña JC
Rev Invest Clin; 1990; 42(3):210-6. PubMed ID: 2270368
[TBL] [Abstract][Full Text] [Related]
64. The pathophysiology of edema formation in the nephrotic syndrome.
Siddall EC; Radhakrishnan J
Kidney Int; 2012 Sep; 82(6):635-42. PubMed ID: 22718186
[TBL] [Abstract][Full Text] [Related]
65. Insulin-like growth factor I and its binding proteins in the experimental nephrotic syndrome.
Hirschberg R; Kaysen GA
Endocrinology; 1995 Apr; 136(4):1565-71. PubMed ID: 7534704
[TBL] [Abstract][Full Text] [Related]
66. Retrobulbar Sinus Injection of Doxorubicin is More Efficient Than Lateral Tail Vein Injection at Inducing Experimental Nephrotic Syndrome in Mice: A Pilot Study.
Bohnert BN; Dörffel T; Daiminger S; Calaminus C; Aidone S; Falkenau A; Semrau A; Le MJ; Iglauer F; Artunc F
Lab Anim; 2019 Dec; 53(6):564-576. PubMed ID: 30678519
[TBL] [Abstract][Full Text] [Related]
67. Hiponatremia during pregnancy with adriamycin-induced nephrotic syndrome in rats.
Pedrycz A; Czerny K; Wieczorski M; Hernik D
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):86-90. PubMed ID: 15323171
[TBL] [Abstract][Full Text] [Related]
68. Hereditary nephrotic syndrome with progression to renal failure in a mouse model (ICGN strain): clinical study.
Ogura A; Asano T; Suzuki O; Yamamoto Y; Noguchi Y; Kawaguchi H; Yamaguchi Y
Nephron; 1994; 68(2):239-44. PubMed ID: 7830863
[TBL] [Abstract][Full Text] [Related]
69. Development of canine nephrotic syndrome model.
Choi EW; Lee CW
J Vet Med Sci; 2004 Feb; 66(2):169-74. PubMed ID: 15031545
[TBL] [Abstract][Full Text] [Related]
70. The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.
Pereira Wde F; Brito-Melo GE; Guimarães FT; Carvalho TG; Mateo EC; Simões e Silva AC
Inflamm Res; 2014 Jan; 63(1):1-12. PubMed ID: 24121975
[TBL] [Abstract][Full Text] [Related]
71. Clinical Features of Nephrotic Syndrome with Cerebral Hemorrhage.
Yang M; Pan X; Liang Z; Huang X; Duan M; Cai H; Yu L; Chen L
Med Sci Monit; 2019 Mar; 25():2179-2185. PubMed ID: 30904921
[TBL] [Abstract][Full Text] [Related]
72. Animal models to induce renal failure: a historical survey.
Strauch M; Gretz N
Contrib Nephrol; 1988; 60():1-8. PubMed ID: 3278849
[No Abstract] [Full Text] [Related]
73. Pathophysiology, Evaluation, and Management of Edema in Childhood Nephrotic Syndrome.
Ellis D
Front Pediatr; 2015; 3():111. PubMed ID: 26793696
[TBL] [Abstract][Full Text] [Related]
74. Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin.
Clarke BV; Harwood KV; Donehower R
J Natl Cancer Inst; 1989 Sep; 81(17):1331-2. PubMed ID: 2769786
[No Abstract] [Full Text] [Related]
75. Cholinesterase activity of rat serum following renal damage.
Raab W
Clin Chim Acta; 1969 Apr; 24(1):135-8. PubMed ID: 5780156
[No Abstract] [Full Text] [Related]
76. Catalpol alleviates adriamycin-induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro.
Zhang J; Bi R; Meng Q; Wang C; Huo X; Liu Z; Wang C; Sun P; Sun H; Ma X; Wu J; Liu K
Br J Pharmacol; 2019 Dec; 176(23):4558-4573. PubMed ID: 31378931
[TBL] [Abstract][Full Text] [Related]
77. A Review of Podocyte Biology.
Garg P
Am J Nephrol; 2018; 47 Suppl 1():3-13. PubMed ID: 29852492
[TBL] [Abstract][Full Text] [Related]
78. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease.
Okuda S; Oh Y; Tsuruda H; Onoyama K; Fujimi S; Fujishima M
Kidney Int; 1986 Feb; 29(2):502-10. PubMed ID: 3486312
[TBL] [Abstract][Full Text] [Related]
79. Rodent models to study sodium retention in experimental nephrotic syndrome.
Xiao M; Bohnert BN; Grahammer F; Artunc F
Acta Physiol (Oxf); 2022 Jul; 235(3):e13844. PubMed ID: 35569011
[TBL] [Abstract][Full Text] [Related]
80. Minimal Change Disease.
Vivarelli M; Massella L; Ruggiero B; Emma F
Clin J Am Soc Nephrol; 2017 Feb; 12(2):332-345. PubMed ID: 27940460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
